Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 2 (2005), Issue 12 (December)

1. Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT).
   Bone Marrow Transplant, 36(12): 1065-9. [Abstract] [Full-text]
2. The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study.
   Bone Marrow Transplant, 36(12): 1043-7. [Abstract] [Full-text]
3. High yield bacterial expression of active c-Abl and c-Src tyrosine kinases.
   Protein Sci, 14(12): 3135-9. [Abstract] [Full-text]
4. c-kit Expression and mutations in peripheral T cell lymphomas, except for extra-nodal NK/T cell lymphomas.
   Leuk Lymphoma, 47(2): 267-70. [Abstract] [Full-text]
5. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment.
   Leuk Lymphoma, 47(1): 155-7. [Abstract] [Full-text]
6. A phase II trial of imatinib in patients with refractory/relapsed myeloma.
   Leuk Lymphoma, 47(1): 39-42. [Abstract] [Full-text]
7. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?
   Leuk Lymphoma, 47(1): 1-7. [Abstract] [Full-text]
8. Gastrointestinal stromal tumor in a child and review of the literature.
   Pediatr Surg Int, 21(11): 914-7. [Abstract] [Full-text]
9. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature.
   Ann Hematol, 85(1): 1-16. [Abstract] [Full-text]
10. A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib.
    J Am Coll Cardiol, 46(11): 1999-2003. [Abstract] [Full-text]
11. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
    Oncology, 69(4): 326-32. [Abstract] [Full-text]
12. Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term.
    J Hepatol, 44(1): 167-75. [Abstract] [Full-text]
13. Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice.
    Arthritis Rheum, 52(12): 3987-96. [Abstract] [Full-text]
14. Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice.
    Cancer Cell, 8(6): 467-78. [Abstract] [Full-text]
15. Hydroxyurea and splenic irradiation-induced tumour lysis syndrome: a case report and review of the literature.
    J Clin Pharm Ther, 30(6): 623-5. [Abstract] [Full-text]
16. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
    Eur J Haematol, 76(1): 9-17. [Abstract] [Full-text]
17. Pharmacokinetic and clinical phase ii trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma.
    Oncology, 69(5): 363-71. [Abstract] [Full-text]
18. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia.
    Biochim Biophys Acta, 1754(1): 3-13. [Abstract] [Full-text]
19. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
    J Clin Oncol, 23(36): 9359-68. [Abstract] [Full-text]
20. Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential.
    Clin Cancer Res, 11(24): 8557-63. [Abstract] [Full-text]
21. The radiology of gastrointestinal stromal tumours (GIST).
    Cancer Imaging, 5: 150-6. [Abstract] [Full-text]
22. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.
    Blood, 107(1): 205-12. [Abstract] [Full-text]
23. Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala.
    Mol Cancer Ther, 4(12): 2008-15. [Abstract] [Full-text]
24. Molecular interactions in imatinib-DPPC liposomes.
    Eur J Pharm Sci, 27(2): 205-11. [Abstract] [Full-text]
25. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake.
    Cell, 123(7): 1293-305. [Abstract] [Full-text]
26. Granulocytic sarcoma giant in chronic myeloid leukemia during imatinib mesylate therapy.
    Am J Hematol, 81(1): 76-77. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.